NY-APOLLO-GLOBAL
12.3.2018 14:02:05 CET | Business Wire | Press release
Certain funds affiliated with Apollo Global Management, LLC (together with its consolidated subsidiaries, “Apollo”) (NYSE: APO) today announced a strategic partnership with Realty Partners to selectively invest in the Italian real estate market.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180312005291/en/
The strategy is to invest in assets, which have potential for value enhancement (through conversions, restructuring, market repositioning). Assets can originate from ordinary and extraordinary disposals, acquisitions of real estate companies or investments in secured NPLs.
“Italy - comments Roger Orf, Partner, European Principal Finance and Head of Real Estate for Europe at Apollo - is a key market in terms of real estate growth forecast in forthcoming years . We wanted to reinforce our presence through a partnership with highly skilled professionals that share our value oriented approach to investing, and this is the reason why we took the decision to work with Realty Partners.”
“We are very pleased - adds Steve McElwain, Partner, European Principal Finance at Apollo - to deepen our investments activities in the Italian real estate market and we hope to deploy a meaningful amount of capital in the next few years. Realty Partners has a track-record of success across all macro environments and an established origination and execution expertise that complements our team.”
Luca de Ambrosis Ortigara, Founding Partner of Realty Partners comments: “We are honoured Apollo has chosen to invest in our Country alongside us and view it as an important act of trust and confidence. We believe our experience across a broad range of asset types and professional approach to sourcing and asset management activities will help Apollo access compelling opportunities and implement strategies to unlock value.”
“We are excited to be Apollo’s preferred partner here in Italy - continues Umberto Vitiello, Founder of Realty Partners - helping to manage the full investment process from acquisitions to disposals. Our goal is to provide both capital and industrial expertise to create significant value in a highly demanding and continuously evolving marketplace.”
Andrea Moneta, Senior Advisor Italy and Operating Partner for Financial Services at Apollo concluded: "I am delighted Luca and Umberto agreed to partner with us to expand our real estate capabilities in Italy, and look forward to working with them. The agreement with Realty Partners represents the third of a series of recent initiatives announced by Apollo (along with recently announced partnerships with DeA Capital for investments in NPLs and Apeiron Management for investments in Illiquid Credit) to capitalize on the opportunity for Apollo to provide tailored solutions addressing the specific needs of the Italian market. "
NOTES TO EDITORS
About Apollo Global Management
Apollo is a leading global alternative investment manager with offices in New York, Los Angeles, Houston, Chicago, Bethesda, Toronto, London, Frankfurt, Madrid, Luxembourg, Mumbai, Delhi, Singapore, Hong Kong and Shanghai. Apollo had assets under management (AUM) of approximately $249 billion as of December 31, 2017 in Private Equity, Credit and Real Assets invested across a core group of nine industries where Apollo has considerable knowledge and resources. For more information about Apollo, please visit www.agm.com
About Realty Partners
Realty Partners has been founded in 2003 by distinguished professionals, Giulio Malfatto, Umberto Vitiello and Luca de Ambrosis Ortigara, with an extensive and unparalleled real estate track record, in order to support third party investors as local strategic operating platform, while generating value and attractive risk adjusted returns across the entire real estate value chain. Independence, integrated model, interests’ alignment, ethics and transparency are its main core values. Realty Partners’ team, based in Milan, is now led by two managing partners, Umberto Vitiello and Luca de Ambrosis Ortigara, who have worked together for more than 20 years, along with Vincenzo Buonocore and Fausto Maria Monachesi, reaching over 100 years of combined experience.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180312005291/en/
Contact:
For investor inquiries regarding Apollo:
Apollo Global
Management, LLC
Gary M. Stein, 212-822-0467
Head of Corporate
Communications
gstein@apollolp.com
or
Apollo
Global Management, LLC
Noah Gunn, 212-822-0540
Investor
Relations Manager
ngunn@apollolp.com
or
For
media inquiries regarding Apollo:
Rubenstein Associates, Inc.
for Apollo Global Management, LLC
Charles Zehren, 212-843-8590
czehren@rubenstein.com
or
For
inquiries regarding Realty Partners:
info@realtypartners.it
or
Press
Office
SEC and Partners
Michele Calcaterra or Matteo Steinbach
+39
026249991
calcaterra@secrp.com
steinbach@secrp.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom